PELAGOS PHARMACEUTICALS, INC.

Houston, TX · Biotech · Private

Small molecule REV-ERB agonists to suppress neuroinflammation in Alzheimer's disease

pelagospharma.com →
Grants
$631K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Developing Novel REV-ERB Agonists for the Treatment of Neuroinflammation in Alzheimer's Disease$540,432
Federal grantDepartment of Health and Human Services · Phase I · Developing Novel REV-ERB Agonists for the Treatment of Neuroinflammation in Alzheimer's Disease$90,950
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1669RYBODYN, INC.——
1670AXONEURAL THERAPEUTICS, INC.——
1671Ef Therapeutics LLC——
1672PELAGOS PHARMACEUTICALS, INC.——
1673Shire Pharmaceuticals——
1674PHOTOCHEM TECHNOLOGIES, LLC——
1675Deep Creek Pharma, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Rev-erb Agonistsapplication
  • Rev-erb Agonistsapplication
  • Rev-erb Agonistsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.